Design, synthesis and in vivo study of novel pyrrolidine-based 11β-HSD1 inhibitors for age-related cognitive dysfunction

R. Leiva, C. Griñan-Ferré, C. Seira, E. Valverde, A. McBride, M. Binnie, B. Pérez, F.J. Luque, M. Pallàs, A. Bidon-Chanal, S.P. Webster, S. Vázquez

Producció científica: Contribució a revistaArticleRecercaAvaluat per experts

15 Cites (Scopus)

Resum

Recent findings suggest that treatment with 11β-HSD1 inhibitors provides a novel approach to deal with age-related cognitive dysfunctions, including Alzheimer's disease. In this work we report potent 11β-HSD1 inhibitors featuring unexplored pyrrolidine-based polycyclic substituents. A selected candidate administered to 12-month-old SAMP8 mice for four weeks prevented memory deficits and displayed a neuroprotective action. This is the first time that 11β-HSD1 inhibitors have been studied in this broadly-used mouse model of accelerated senescence and late-onset Alzheimer's disease.
Idioma originalAnglès
Pàgines (de-a)412-428
Nombre de pàgines17
RevistaEuropean Journal of Medicinal Chemistry
Volum139
DOIs
Estat de la publicacióPublicada - 20 d’oct. 2017

Fingerprint

Navegar pels temes de recerca de 'Design, synthesis and in vivo study of novel pyrrolidine-based 11β-HSD1 inhibitors for age-related cognitive dysfunction'. Junts formen un fingerprint únic.

Com citar-ho